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ABSTRACT	
	
Colorectal	cancer	(CRC)	is	the	third	most	common	cancer	in	economically	developed	countries	
and	 a	major	 cause	of	 cancer-related	mortality.	 The	 importance	of	 lifestyle	 and	diet	 as	major	
determinants	of	CRC	risk	is	suggested	by	differences	in	CRC	incidence	between	countries	and	in	
migration	 studies.	 Previous	observational	 epidemiological	 studies	have	 identified	associations	
between	modifiable	environmental	risk	factors	and	CRC,	but	these	studies	can	be	susceptible	to	
reverse	 causation	 and	 confounding,	 and	 their	 results	 can	 therefore	 conflict.	 Mendelian	
randomisation	 (MR)	 analysis	 represents	 an	 approach	 complementary	 to	 conventional	
observational	studies	examining	associations	between	exposures	and	disease.	The	MR	strategy	
employs	 allelic	 variants	 as	 instrumental	 variables	 (IVs),	 which	 act	 as	 proxies	 for	 non-genetic	
exposures.	 These	 allelic	 variants	 are	 randomly	 assigned	 during	 meiosis	 and	 can	 therefore	
inform	on	life-long	exposure,	whilst	not	being	subject	to	reverse	causation.	In	previous	studies	
MR	 frameworks	have	associated	 several	modifiable	 factors	with	CRC	 risk,	 including	adiposity,	
hyperlipidaemia,	fatty	acid	profile	and	alcohol	consumption.	In	this	review	we	detail	the	use	of	
MR	to	investigate	and	discover	CRC	risk	factors,	and	its	future	applications.		
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1.	INTRODUCTION	
	
Colorectal	 cancer	 (CRC)	 is	 one	 of	 the	 most	 common	 cancers	 in	 economically	 developed	
countries	and	a	major	 cause	of	 cancer-related	mortality	 (Forman	et	al.,	 2014).	 The	disease	 is	
currently	diagnosed	in	over	one	million	individuals	worldwide	annually;	although	its	incidence	is	
set	to	rise	in	developing	countries	with	the	adoption	of	western	lifestyles	and	diets	(Haggar	and	
Boushey,	2009).	 The	 importance	of	 lifestyle	and	diet	 as	major	determinants	of	CRC	 risk	have	
been	 strongly	 suggested	 by	 geographical	 differences	 in	 CRC	 incidence	 and	 demonstrated	 in	
migration	studies	(Kamangar	et	al.,	2006).	Given	the	importance	of	these	factors	in	CRC	risk,	the	
modification	 of	 lifestyle	 and	 diet	 through	 public	 health	 initiatives	 offers	 the	 prospect	 of	
significant	impact	on	CRC	incidence.	The	full	compendium	of	exposures	affecting	CRC	risk,	and	
their	 relative	 contributions,	 has	 yet	 to	 be	 elucidated	 however,	 necessitating	 further	work	 to	
discover	and	validate	risk	factors.		
	
	
2.	ESTABLISHED	AND	POSTULATED	COLORECTAL	CANCER	RISK	FACTORS	
	
Both	environmental	and	genetic	factors	play	important	roles	in	CRC	aetiology.	The	majority	of	
CRCs	are	sporadic,	with	approximately	80%	of	patients	presenting	without	a	 family	history	of	
the	 disease	 (Winawer	 et	 al.,	 1997).	 The	 lifetime	 risk	 for	 CRC	 in	 Western	 populations	 is	
approximately	4%	(Siegel	et	al.,	2017),	although	this	risk	is	almost	doubled	in	individuals	with	a	
first-degree	 family	member	 diagnosed	with	 CRC,	 and	 tripled	 in	 individuals	with	 two	 or	more	
affected	 family	members	 (Taylor	et	al.,	 2010).	 Epidemiological	 studies	have	provided	 support	
for	a	hereditary	component	to	the	aetiology	of	a	large	number	of	cancers,	including	CRC	(Risch,	
2001).	 For	 many	 cancers,	 a	 higher	 concordance	 in	 monozygotic	 twins	 as	 compared	 with	
dizygotic	 twins,	 or	 with	 siblings,	 has	 been	 observed	 (Lichtenstein	 et	 al.,	 2000).	 Whilst	 such	
concordance	 is	 compatible	 with	 inherited	 genetic	 variation	 affecting	 risk,	 non-genetic	
mechanisms	cannot	be	excluded	as	a	basis	of	the	measured	heritability.		
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Technological	 developments	 in	 high-throughput	 genotyping	 and	 improved	 understanding	 of	
common	 genetic	 variation	 have	 made	 genome-wide	 association	 studies	 (GWAS)	 possible,	
facilitating	the	identification	of	single	nucleotide	polymorphisms	(SNPs)	influencing	cancer	risk	
(Sud	 et	 al.,	 2017).	 So	 far,	 GWAS	 have	 identified	 approximately	 100	 SNPs	 independently	
associated	 with	 CRC	 risk	 (Al-Tassan	 et	 al.,	 2015;	 Broderick	 et	 al.,	 2007;	 Cogent	 Study	 et	 al.,	
2008;	Dunlop	et	al.,	2012;	Houlston	et	al.,	2010;	Kinnersley	et	al.,	2012;	Orlando	et	al.,	2016;	
Schumacher	et	al.,	2015;	Tenesa	et	al.,	2008;	Tomlinson	et	al.,	2007;	Whiffin	et	al.,	2014),	with	
the	 largest	study	to-date	combining	data	from	over	125,000	 individuals	 (Huyghe	et	al.,	2018).	
The	 identification	of	 these	 risk	variants	has	contributed	 to	an	 improved	understanding	of	 the	
pathways	and	mechanisms	influencing	CRC	development.			
	
Multiple	lifestyle	and	environmental	factors,	many	of	which	are	modifiable,	are	now	known	to	
influence	CRC	risk	(Kuipers	et	al.,	2015;	World	Cancer	Research	Fund,	2017).	The	World	Cancer	
Research	Fund	(2017)	conducted	a	systematic	analysis	of	known	and	suspected	CRC	risk	factors,	
categorizing	them	into	those	with	strong	and	limited	evidence	for	a	causal	relationship.	Strong	
evidence	 is	 reported	 for	 factors	 including	obesity,	 height,	 alcohol	 intake	 and	 consumption	of	
red	 and	 processed	 meats	 increasing	 CRC	 risk.	 The	 evidence	 that	 low	 intake	 of	 non-starchy	
vegetables	 and	 fruits	 and	 high	 intake	 of	 foods	 containing	 iron	 increases	 risk	 of	 CRC	 was	
reported	as	weaker.	The	World	Cancer	Research	Fund	report	also	highlighted	physical	activity,	
the	consumption	of	whole	grains,	fibre,	dairy	products	and	the	use	of	calcium	supplements	as	
being	strongly	associated	with	lower	CRC	risk.	Evidence	that	use	of	multivitamin	supplements,	
and	foods	containing	vitamins	C	and	D	decreases	risk	of	CRC	was	reported	as	weaker.			
	
Increased	 CRC	 risk	 has	 also	 been	 associated	 with	 chronic	 colitis	 due	 to	 inflammatory	 bowel	
disease	(IBD)	(Lu	et	al.,	2018).	The	longer	the	duration	of	IBD,	the	greater	the	increase	in	CRC	
risk	(Lu	et	al.,	2018).	However,	whilst	 IBD	is	thought	to	 increase	risk	of	CRC,	 it	explains	only	a	
small	 proportion	 of	 CRC	 incidence	 in	 Western	 populations	 (Kuipers	 et	 al.,	 2015).	 Improved	
surveillance	 and	 the	 increasing	 effectiveness	 of	 anti-inflammatory	 treatments	 may	 also	 be	
lowering	 the	 incidence	 of	 CRC	 in	 those	 with	 IBD	 (Jess	 et	 al.,	 2012).	 Heavy	 smoking	 over	 a	
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prolonged	period	 is	 also	 increasingly	 being	 recognised	 as	 being	 associated	with	 an	 increased	
CRC	risk,	in	the	region	of	an	additional	11	cases	per	100,000	person-years	(Botteri	et	al.,	2008).		
	
The	influence	of	modifiable	environmental	and	lifestyle	risk	factors	is	likely	to	partly	explain	the	
socioeconomic	 and	 geographic	 differences	 in	 CRC	 rates	 (Doubeni	 et	 al.,	 2012).	 It	 has	 been	
estimated	that	as	many	as	71%	of	CRCs	in	Western	countries	may	be	due	to	these	modifiable	
exposures	 and	 therefore	 preventable	 (Platz	 et	 al.,	 2000).	 However,	 to	 reduce	 CRC	 incidence	
through	 public	 health	 initiatives,	 it	 is	 imperative	 to	 determine	which	 factors	 associated	with	
CRC	risk	are	causally	related,	and	which	are	simply	correlated.		
	
	
3.	APPROACHES	FOR	RISK	FACTOR	DISCOVERY	AND	VALIDATION	
	
3.1.	Observational	epidemiological	studies	
So	 far,	 many	 studies	 attempting	 to	 evaluate	 relationships	 between	 possible	 risk	 factors	 and	
diseases,	 such	as	CRC,	have	 relied	upon	observational	 case-control,	 cohort,	or	 cross-sectional	
study	 designs	 (Lawlor	 et	 al.,	 2004).	 Whilst	 observational	 studies	 have	 seemingly	 robustly	
associated	a	risk	factor	and	a	disease,	 interventions	modifying	such	risk	factors	do	not	always	
results	 in	 the	 anticipated	 change	 in	 disease	 incidence	 (Davey	 Smith	 and	 Hemani,	 2014).	 A	
number	 of	 explanations	 for	 these	 ostensibly	 paradoxical	 observations	 have	 been	 suggested,	
including	 the	 susceptibility	of	observational	epidemiological	 studies	 to	 certain	biases,	 such	as	
reverse	 causation,	 confounding	 and	 errors	 in	 measurement.	 These	 biases	 can	 result	 in	 an	
apparent	 association	 between	 a	 risk	 factor	 and	 a	 disease,	 without	 the	 existence	 of	 a	 direct	
causal	relationship.		
	
Reverse	 causation	 occurs	 when	 the	 postulated	 risk	 factor	 does	 not	 itself	 influence	 disease	
development,	but	 instead	the	occurrence	of	 the	disease	affects	 the	postulated	risk	 factor.	An	
example	of	possible	reverse	causation	is	in	the	relationship	between	computerized	tomography	
(CT)	 scans	and	cancer	 (Mathews	et	al.,	2013).	 	Higher	cancer	 incidence	has	been	observed	 in	
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individuals	 exposed	 to	 low-dose	 ionizing	 radiation	 from	diagnostic	 CT	 scans	 (Mathews	 et	 al.,	
2013).	 However,	 it	 is	 difficult	 to	 exclude	 the	 possibility	 that	 the	 symptoms	 of	 precancerous	
conditions,	 or	 early	 cancer	 symptoms,	 led	 to	 patients	 having	 CT	 scans.	 Retrospective	 studies	
that	 seek	 to	 establish	 risk	 factors	 after	 disease	 diagnosis	 are	 especially	 susceptible	 to	 such	
reverse	causation.	
	
Confounders	 are	 factors	 causally	 related	 to	 both	 the	 postulated	 risk	 factor	 and	 the	 disease	
under	 consideration.	 For	 instance,	 smoking	 has	 been	 associated	 with	 increased	 risk	 of	 CRC	
(Botteri	 et	 al.,	 2008).	 However,	 smoking	 may	 be	 associated	 with	 other	 CRC	 risk	 factors,	
including	alcohol	consumption,	physical	inactivity	and	low	uptake	of	CRC	screening	(Chao	et	al.,	
2000).	An	individual	who	consumes	more	alcohol	is	indeed	more	likely	to	smoke,	and	if	alcohol	
consumption	is	causally	related	to	CRC	development,	then	this	confounder	could	partly	explain	
the	 association	 between	 smoking	 and	 CRC	 incidence.	 As	 such	 confounders	 are	 often	 not	
measured	in	observational	epidemiological	studies,	it	may	not	always	be	possible	to	control	for	
them	when	evaluating	risk	factors.	Furthermore,	unidentified	confounders	may	exist,	resulting	
in	additional	bias	 that	 could	be	 impossible	 to	account	 for	 in	a	 traditional	observational	 study	
design.		
	
3.2.	Mendelian	randomization	
The	 gold	 standard	 for	 inferring	 causality	 is	 a	 randomized	 control	 trial	 (RCT).	 Individuals	 in	 an	
RCT	 are	 randomly	 assigned	 to	 two	 or	 more	 groups,	 minimizing	 both	 selection	 bias	 and	
confounding.	As	groups	are	assigned	at	the	start	of	the	study,	reverse	causation	can	be	avoided.	
RCTs	are	however	often	not	possible	due	to	the	costs	or	the	time	required.	Furthermore,	RCTs	
can	have	 short	 follow-up	 times	and	hence	only	 reflect	 the	effect	of	 an	exposure	at	 a	 certain	
time	in	life.	It	is	also	not	always	possible	to	assign	individuals	to	groups	to	evaluate	certain	risk	
factors	because	of	practical	or	ethical	concerns.		
	
Mendelian	randomisation	(MR)	uses	genetic	variants,	such	as	SNPs,	as	proxies	for	exposures	to	
determine	 the	 effect	 of	 an	 exposure	 on	 an	 outcome	 (Sheehan	 et	 al.,	 2008).	 In	 the	 general	
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population,	 germline	 variants	 tend	 to	 be	 randomly	 distributed	 with	 respect	 to	 most	 human	
traits.	 This	 occurs	 because	 of	 the	 fixed	 nature	 of	 germline	 genotypes	 and	Mendel’s	 laws	 of	
inheritance	 (i.e.	 segregation	and	 independent	assortment).	Using	germline	variants	as	proxies	
for	 an	 exposure	 therefore	 ensures	 that	 MR	 is	 less	 susceptible	 to	 biases	 that	 affect	 many	
observational	 epidemiological	 studies	 (Davey	 Smith	 and	 Hemani,	 2014).	 For	 example,	 as	
genotypes	are	randomly	assigned	at	conception,	MR	is	not	biased	by	reverse	causation.	MR	can	
therefore	be	considered	analogous	to	a	natural	RCT.	Furthermore,	as	genotypes	are	present	at	
conception,	MR	analyses	can	examine	the	lifetime	effect	of	an	exposure	on	disease	risk,	unlike	
other	study	designs.		
	
MR	analyses	 involve	three	main	assumptions:	 (i)	 the	genetic	variants	used	as	 IVs	are	robustly	
associated	 with	 the	 exposure	 under	 consideration;	 (ii)	 these	 IVs	 are	 independent	 of	
confounding	factors;	and	(iii)	the	IVs	are	only	associated	with	the	outcome	under	consideration	
via	the	exposure	(Lawlor	et	al.,	2008).	These	three	assumptions	are	often	depicted	as	a	directed	
acyclic	graph	(Figure	1).	The	satisfaction	of	these	three	assumptions	is	sufficient	to	test	the	null	
hypothesis	 that	 the	 exposure	 is	 not	 causally	 related	 to	 the	outcome.	However,	 to	 accurately	
estimate	the	size	of	the	effect,	a	fourth	additional	assumption	is	required:	(iv)	all	associations	
depicted	 in	 Figure	 1	 are	 unaffected	 by	 statistical	 interactions	 and	 are	 linear	 (Lawlor	 et	 al.,	
2008).	Considering	these	assumptions,	genetic	variants	can	be	used	a	proxies	for	a	large	range	
of	modifiable	risk	factors.	In	one-sample	MR,	a	single	data	set	containing	all	information	on	the	
genetic	variants,	the	exposure	and	the	outcome	for	all	individuals	is	used	to	assess	a	potential	
causal	relationship	(Haycock	et	al.,	2016).	 In	practice,	few	data	sets	contain	exposure	data	for	
all	individuals	and	a	sufficient	number	of	disease	cases	and	controls	to	conduct	one-sample	MR	
analyses	with	sufficient	power	to	identify	causal	effects.	This	has	prompted	the	development	of	
two-sample	MR	strategies,	which	use	data	from	separate	data	sets:	one	containing	information	
on	 genetic	 variants	 and	 the	exposure	of	 interest,	 and	 another	 containing	 information	on	 the	
same	genetic	variants	and	the	considered	outcome	(Hartwig	et	al.,	2016).	For	many	risk	factors	
and	 cancers,	 GWAS	 containing	 data	 from	 tens	 or	 hundreds	 of	 thousands	 of	 individuals	 have	
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been	completed	 (Sud	et	al.,	 2017),	 facilitating	 the	use	of	 two-sample	MR	 to	 study	 the	causal	
relationship	between	various	exposures	and	diseases.	
	
One	of	the	central	tenets	of	MR	is	the	absence	of	pleiotropy	(i.e.	a	variant	influencing	multiple	
traits)	between	the	SNPs	associated	with	the	exposure	and	outcome	(Davey	Smith	and	Hemani,	
2014).	Directional	pleiotropy	can	result	 in	the	false	 identification	of	an	association	between	a	
putative	 exposure	 and	outcome,	 or	 the	 failure	 to	 identify	 a	 true	 causal	 relationship	 (Burgess	
and	 Thompson,	 2017).	 Multiple	 methods	 have	 been	 developed	 to	 assess	 whether	 such	
directional	pleiotropy	exists	and	avoid	it	biasing	causal	estimates.	 In	MR-Egger	regression,	the	
slope	coefficient	from	Egger	regression	is	used	to	assess	directional	pleiotropy	(Bowden	et	al.,	
2015).	MR-Egger	regression	relies	on	the	assumption	that	the	pleiotropic	effects	of	each	variant	
are	 independently	distributed	 from	the	genetic	association	with	 the	outcome;	an	assumption	
referred	 to	 as	 InSIDE	 (INstrument	 Strength	 Independent	 of	 Direct	 Effect).	 If	 the	 InSIDE	
assumption	is	satisfied,	then	MR-Egger	causal	effect	estimates	will	be	consistent	as	sample	size	
and	 the	 number	 of	 genetic	 variants	 increase	 (Burgess	 and	 Thompson,	 2017).	 Furthermore,	
under	the	InSIDE	assumption	the	MR-Egger	intercept	term	can	be	used	to	evaluate	the	average	
pleiotropic	effect	across	variants.	 If	 this	average	pleiotropic	effect	 is	 zero,	 then	 the	MR-Egger	
causal	 effect	 estimate	 will	 equal	 causal	 effect	 estimates	 from	 other	 regression-based	 MR	
approaches,	 including	 the	 inverse	 variance	weighted	 (IVW)	method	 (Burgess	 and	 Thompson,	
2017).		
	
Approaches	such	as	the	HEIDI	outlier	test,	 implemented	as	part	of	the	Generalised	Summary-
data-based	Mendelian	Randomisation		(GSMR)	package	(Zhu	et	al.,	2018),	can	also	be	used	to	
identify	and	remove	variants	that	violate	IV	assumptions.	Methods	such	as	simple	and	weighted	
median	estimators	 (Bowden	et	al.,	2016)	and	the	mode-based	estimate	(Hartwig	et	al.,	2017)	
can	produce	unbiased	estimates	of	a	 causal	effect	even	when	 the	majority	of	 IVs	are	 invalid.	
Further	methodological	 developments,	 such	 as	 latent	 causal	 variable	 (LCV)	models,	 allow	 for	
accurate	 inference	 of	 causal	 relationships,	 even	 when	 the	 exposure	 and	 outcome	 are	
genetically	correlated	(O'Connor	and	Price,	2018).	These	methods	also	have	their	disadvantages	
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however,	 with	 MR-Egger,	 median	 estimators	 and	 mode-based	 estimates	 generally	 achieving	
less	power	than	conventional	 IV	approaches	 (Bowden	et	al.,	2015),	and	LCV	models	 requiring	
genome-wide	summary	statistics	for	both	the	exposure	and	outcome	–	data	that	are	not	always	
available.	
	
	
4.	LIMITATIONS	OF	MENDELIAN	RANDOMISATION		
	
Whilst	MR	analyses	complement	observational	epidemiological	studies,	and	are	less	influenced	
by	 some	biases,	 there	are	a	number	of	 limitations	 to	 the	approach.	MR	methods	 rely	on	 the	
availability	of	genetic	instruments	robustly	associated	with	the	exposure	of	interest	that	can	be	
used	as	proxies.	For	some	exposures,	such	as	obesity	and	height,	GWAS	containing	data	from	
hundreds	 of	 thousands	 of	 individuals	 have	 been	 completed,	 resulting	 in	 the	 identification	 of	
hundreds	 of	 exposure-associated	 SNPs	 that	 explain	 a	 high	 proportion	 of	 the	 genetically	
associated	exposure	(Yengo	et	al.,	2018).	For	other	exposures	no	or	few	associated	SNPs	have	
been	 identified,	 thereby	prohibiting	 their	 study	using	MR	 frameworks.	 If	 exposure-associated	
SNPs	 have	 been	 identified,	 but	 these	 SNPs	 explain	 only	 a	 small	 proportion	 of	 exposure	
variation,	then	MR	analyses	may	not	be	sufficiently	powered	to	detect	causal	effects,	especially	
if	the	true	effect	sizes	are	weak	(Smith	and	Ebrahim,	2004).		
	
The	study	of	some	risk	factors	requires	additional	information	not	always	available,	even	when	
using	a	 two-sample	MR	 framework.	For	example,	different	SNPs	are	associated	with	smoking	
initiation	and	number	of	cigarettes	smoked	per	day	(Tobacco	and	Genetics	Consortium,	2010),	
and	it	 is	therefore	necessary	to	stratify	disease	cases	and	controls	by	whether	they	have	ever	
smoked	to	accurately	estimate	the	effect	size	of	smoking	on	disease	risk.	In	many	cancer	GWAS,	
smoking	status	is	not	measured,	prohibiting	the	accurate	assessment	of	effect	size.			
	
Although	 implemented	 in	 a	 number	 of	 studies	 (Ahmad	 et	 al.,	 2015;	 Gage	 et	 al.,	 2017),	
conventional	IV	approaches	in	a	two-sample	setting	may	not	accurately	estimate	the	effect	size	
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of	 a	 binary	 exposure,	 such	 as	 smoking	 initiation,	 on	 a	 binary	 outcome,	 such	 as	 disease	
diagnosis.	 Through	 simulation	 we	 previously	 evaluated	 whether	 IVW,	 weighted	 median	
estimators,	mode-base	estimates	and	MR-Egger	methods	provide	 reliable	estimates	of	 causal	
effects	 when	 considering	 binary	 exposures	 and	 binary	 outcomes	 (Disney-Hogg	 et	 al.,	 2018).	
When	 a	 causal	 relationship	 was	 simulated,	 the	 magnitudes	 of	 the	 effect	 estimates	 were	
inflated,	and	two-sample	MR	frameworks	may	therefore	not	be	suitable	for	assessing	the	effect	
size	of	binary	exposures	on	CRC	risk.		
	
	
5.	MENDELIAN	RANDOMISATION	IN	COLORECTAL	CANCER	RESEARCH	
	
Many	studies	have	 implemented	two-sample	MR	frameworks	to	evaluate	causal	relationships	
between	risk	factors	and	CRC.	Here	we	discuss	findings	and	insights	from	these	studies	(Table	
1).		
	
Several	 studies	have	 investigated	 the	causal	 relationship	between	obesity-related	 factors	and	
CRC	risk.	In	a	study	of	9,254	CRC	cases	and	18,386	controls,	Jarvis	et	al.	(2016)	associated	body	
mass	 index	(BMI)	(OR:	1.23,	95%	CI:	1.02-1.49,	P=0.033),	childhood	obesity	(OR:	1.07,	95%	CI:	
1.03-1.13,	 P=0.018)	 and	 waist-hip	 ratio	 (WHR)	 (OR:	 1.59,	 95%	 CI:	 1.08-2.34,	 P=0.019)	 with	
increased	CRC	risk.	Gao	et	al.	(2016)	similarly	associated	adult	BMI	with	increased	CRC	risk	(OR:	
1.39,	95%	CI:	1.06-1.82,	P=0.016),	but	did	not	find	significant	associations	for	childhood	BMI	or	
WHR,	 possibly	 due	 to	 the	 smaller	 size	 of	 their	 study,	 which	 contained	 5,100	 CRC	 cases	 and	
4,831	 controls.	Many	 obesity-related	 traits	 have	 strong	 genetic	 correlations	 (Bulik-Sullivan	 et	
al.,	2015)	and	further	work	is	therefore	necessary	to	investigate	which	aspects	of	adiposity	have	
the	greatest	influence	on	CRC	risk.		
	
It	has	been	suggested	that	adiponectin,	an	adipocyte-derived	peptide	hormone,	may	mediate	
the	 association	 between	 obesity	 and	 risk	 of	 CRC	 (Vansaun,	 2013).	 Observational	
epidemiological	 studies	 of	 adiponectin	 have	 however	 yielded	 inconsistent	 results,	with	 some	
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associating	 lower	 circulating	 adiponectin	with	 increased	 CRC	 risk	 (Aleksandrova	 et	 al.,	 2012),	
and	others	failing	to	identify	such	association	(Stocks	et	al.,	2008).	MR	analyses	of	adiponectin	
and	 CRC	 risk	 have	 also	 been	 inconsistent.	 In	 a	 multi-ethnic	 meta-analysis,	 Pei	 et	 al.	 (2015)	
considered	 five	 ADIPOQ	 polymorphisms,	 finding	 the	 genotype	 of	 one	 (rs2241766)	 to	 be	
associated	with	CRC	risk	(OR:	1.26,	95%	CI:	1.09-1.47,	P=0.002).	Nimptsch	et	al.	(2017)	created	
an	ADIPOQ	allele	score	explaining	approximately	3%	of	the	variation	in	circulating	adiponectin,	
but	did	not	find	this	to	be	significantly	associated	with	CRC	risk.	Song	et	al.	(2015)	considered	19	
adiponectin-associated	SNPs	and	 similarly	did	not	 find	any	 to	be	 significantly	 associated	with	
the	 risk	 of	 CRC.	 Inconsistencies	 between	 the	 observational	 epidemiological	 and	 MR	 studies	
could	be	due	to	reverse	causation	or	confounding	factors	biasing	the	observational	studies,	or	
because	of	the	relatively	low	power	of	the	MR	analyses	to	identify	a	causal	relationship.		
	
Hyperinsulinemia	 has	 also	 been	 suggested	 to	 be	 associated	 with	 increased	 risk	 of	 CRC.	
Nimptsch	 et	 al.	 (2015b)	 therefore	 used	 an	MR	 framework	 to	 investigate	whether	 fetuin-A,	 a	
liver	 protein	 known	 to	 inhibit	 the	 action	 of	 insulin,	 was	 causally	 related	 to	 CRC	 risk.	 No	
significant	 association	 was	 identified,	 although	 the	 analysis	 contained	 only	 456	 case-control	
pairs,	and	a	small	effect	of	fetuin-A	on	CRC	risk	therefore	cannot	be	excluded.		
	
Development	of	CRC	has	been	positively	correlated	with	circulating	levels	of	plasma	cholesterol	
and	other	components	of	the	lipid	profile	in	prospective	epidemiological	studies	(Yao	and	Tian,	
2015).	 It	 is	 not	 clear	 however	whether	 these	 findings	 reflect	 a	 causal	 relationship	 or	 are	 the	
consequence	of	 confounding	by	 factors	 such	as	a	common	aetiology	of	both	hyperlipidaemia	
and	CRC.	Lipid	levels	can	be	modified	by	both	treatment	with	statins	and	lifestyle	changes	and	
an	understanding	of	the	causal	relationship	with	CRC	is	therefore	 important	when	developing	
CRC	prevention	programs.	The	effect	of	statins,	which	reduce	circulating	cholesterol	levels,	on	
CRC	 risk	 is	highly	 controversial,	with	a	 recent	meta-analysis	of	eight	RCTs	 failing	 to	 identify	a	
significant	beneficial	effect	(Lytras	et	al.,	2014).	Other	analyses	have	however	associated	statin	
usage	 with	 lower	 CRC	 incidence	 (Mamtani	 et	 al.,	 2016).	 Rodriguez-Broadbent	 et	 al.	 (2017)	
employed	 MR	 frameworks	 to	 study	 the	 effects	 of	 blood	 levels	 of	 total	 cholesterol	 (TC),	
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triglycerides	(TG),	low-density	lipoprotein	(LDL)	and	high-density	lipoprotein	(HDL)	on	CRC	risk.	
Higher	concentrations	of	TC	were	associated	with	an	 increased	risk	of	CRC	(OR:	1.46,	95%	CI:	
1.20-1.79,	P=1.68	×	10-4).	Furthermore,	a	genetic	risk	score	for	HMGCR,	simulating	the	effect	of	
statins,	was	associated	with	reduced	CRC	risk	(OR:	0.69,	95%	CI:	0.49-0.99,	P=0.046)	(Rodriguez-
Broadbent	 et	 al.,	 2017).	 This	 study	 therefore	 supports	 a	 causal	 relationship	 between	 TC	 and	
CRC	risk,	providing	further	evidence	that	statin	use	could	be	effective	in	public	health	strategies	
aiming	to	reduce	CRC	incidence.		
	
Dietary	fat	has	been	 implicated	as	a	cancer	risk	 factor,	with	meta-analyses	of	epidemiological	
studies	tending	to	associate	higher	consumption	of	red	and	processed	meat	with	increased	CRC	
risk	(Aykan,	2015).	It	is	unlikely	however	that	the	relationship	between	fat	intake	and	CRC	risk	
depends	 solely	 on	 the	quantity,	 but	 also	 on	 the	 specific	 fatty	 acid	 (FA)	 type.	 Epidemiological	
studies	 and	 animal	 models	 have	 implicated	 animal	 fat	 (Reddy,	 2002),	 some	 omega-6	
polyunsaturated	 fatty	acids	 (PUFAs)	and	saturated	 fatty	acid	 (SFA)	with	 increased	cancer	 risk,	
and	omega-3	PUFA	consumption	with	reduced	cancer	risk	(Azrad	et	al.,	2013).	The	evidence	of	
a	 causal	 relationship	 between	 the	 consumption	 of	 specific	 fatty	 acids	 from	 observational	
epidemiological	 studies	 has	 however	 been	 inconclusive.	 Possible	 reasons	 for	 this	 include	
reverse	 causation,	 confounding	 factors	 and	 inaccurate	 measurement	 of	 long-term	 diet	
(Theodoratou	et	al.,	2007).	Results	from	an	MR	study	by	May-Wilson	et	al.	(2017)	were	broadly	
consistent	 with	 a	 pro-inflammatory	 FA	 profile	 having	 a	 detrimental	 effect	 on	 risk	 of	 CRC.	
Arachidonic	acid	(OR:	1.05,	95%	CI:	1.02-1.07,	P=1.7×10-4)	and	stearic	saturated	FAs	(OR:	1.17,	
95%	CI:	1.01-1.35,	P=0.041)	were	associated	with	increased	CRC	risk,	whilst	oleic	(OR:	0.77,	95%	
CI:	 0.65-0.92,	 P=3.9×10-3)	 and	 palmitoleic	 (OR:	 0.36,	 95%	 CI:	 0.15-0.84,	 P=0.018)	
monounsaturated	FAs,	and	linoleic	polyunsaturated	FAs	(OR:	0.95,	95%	CI:	0.93-0.98,	P=3.7×10-
4)	were	associated	with	reduced	CRC	risk.	In	the	analysis	by	May-Wilson	et	al.	(2017),	the	same	
SNP	(rs102275),	or	a	correlated	SNP	(rs174547),	was	used	to	infer	causal	relationships	between	
multiple	 FAs	 and	 risk	of	 CRC.	 These	 SNPs	were	used	assuming	 that	 the	exposure	 individually	
accounts	 for	 the	effect	on	CRC,	and	 the	effect	of	 the	genetic	variant	on	CRC	 risk	 is	 therefore	
counted	 twice,	 in	 that	 it	 is	 assigned	 to	 multiple	 FA	 exposures	 (Holmes	 et	 al.,	 2017).	
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Consequently,	such	single	locus	MR	analyses	are	unable	to	determine	which	FA	primarily	drives	
the	relationship	between	FA	profile	and	CRC	risk.		
	
Chronic	 inflammation	has	been	 identified	as	a	 risk	 factor	 for	CRC	 (Grivennikov,	2013).	Higher	
concentrations	 of	 C-reactive	 protein	 (CRP),	 a	 marker	 of	 inflammation,	 have	 been	 associated	
with	 an	 increased	 risk	 of	 CRC	 in	 observational	 epidemiological	 studies	 (Tsilidis	 et	 al.,	 2008).	
Considering	only	observational	studies	it	is	unclear	however	whether	this	relationship	is	causal,	
or	a	result	of	confounding	factors.	Wang	et	al.	(2018)	conducted	the	largest	MR	analysis	of	CRP	
concentration	 and	 CRC	 risk	 to-date,	 and	 failed	 to	 find	 evidence	 that	 CRP	 concentrations	 are	
causally	related	to	risk	of	CRC.	Nimptsch	et	al.	(2015a)	conversely	found	a	positive	relationship	
between	CRP	concentrations	and	CRC	risk	(OR:	1.74,	95%	CI:	1.06-2.85).	However,	the	study	by	
Nimptsch	 et	 al.	 (2015a)	 considered	 only	 727	 CRC	 cases	 and	 727	 controls,	whilst	Wang	 et	 al.	
(2018)	 used	 data	 from	 30,480	 CRC	 cases	 and	 22,844	 controls.	 This	 suggests	 that	 the	 causal	
relationship	reported	by	Nimptsch	et	al.	(2015a)	may	be	a	false	positive.		
	
Numerous	studies	have	associated	height	with	increased	risk	of	cancers,	including	breast,	CRC,	
leukemia,	 non-Hodgkin	 lymphoma	 and	 malignant	 melanoma	 (Green	 et	 al.,	 2011).	 GWAS	 of	
height	 encompassing	 more	 than	 half	 a	 million	 individuals	 have	 been	 conducted,	 identifying	
SNPs	 that	 explain	 a	 substantial	 proportion	 of	 height	 variation	 (Yengo	 et	 al.,	 2018),	 and	MR	
frameworks	are	therefore	well	suited	to	investigate	the	causal	relationship	between	height	and	
CRC.	 Using	 data	 from	 10,226	 CRC	 cases	 and	 10,286	 controls,	 Thrift	 et	 al.	 (2015a)	 found	 a	
positive	 association	 between	 height	 and	 CRC	 risk	 (OR:	 1.07,	 95%	 CI:	 1.01-1.14).	 In	 a	 smaller	
study	 of	 5,100	 cases	 and	 4,831	 controls,	 Khankari	 et	 al.	 (2016)	 also	 reported	 a	 positive	
association	(OR:	1.58,	95%	CI:	1.14-2.18,	P=0.006).	
	
Epidemiological	 studies	 of	 the	 effect	 of	 reproductive	 factors	 on	 risk	 of	 CRC	 have	 not	 been	
consistent	 (Martinez	 et	 al.,	 1997;	 Tsilidis	 et	 al.,	 2010).	Neumeyer	 et	 al.	 (2018)	 employed	MR	
frameworks	to	study	the	effect	of	age	at	menarche	and	age	at	menopause	on	CRC	risk,	using	
data	from	12,944	women	diagnosed	with	CRC,	and	10,741	women	without	CRC,	identifying	no	
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significant	associations.	The	SNPs	used	as	IVs	for	these	reproductive	factors	explain	only	a	small	
proportion	of	their	variance	however,	and	therefore	although	this	study	used	data	from	a	large	
number	 of	 CRC	 cases	 and	 controls,	 it	 had	 limited	 power	 to	 detect	 weak	 causal	 effects.	
Nevertheless,	 these	 results	 suggest	 that	 it	 is	 unlikely	 that	 age	 at	menarche	 and	menopause	
have	substantial	causal	effects	on	CRC	risk.		
	
Polymorphisms	 altering	 the	 conversion	 rates	 of	 alcohol-metabolizing	 enzymes,	 leading	 to	 a	
build-up	 of	 excess	 acetaldehyde	 and	 thereby	 reducing	 heavy	 alcohol	 use,	 are	 prevalent	 in	
certain	Asian	populations	(Eng	et	al.,	2007).	These	polymorphisms,	such	as	Glu487Lys	in	ALDH2,	
therefore	 offer	 the	 opportunity	 to	 use	 MR	 frameworks	 to	 investigate	 the	 effect	 of	 alcohol	
consumption	 on	 various	 traits.	Wang	 et	 al.	 (2011)	 conducted	 a	meta-analysis	 of	MR	 studies	
using	the	Glu487Lys	polymorphism	to	examine	the	relationship	between	alcohol	consumption	
and	 risk	 of	 CRC,	 finding	 higher	 genetically	 predicted	 alcohol	 intake	 to	 be	 associated	 with	
increased	CRC	risk	(OR:	1.31,	95%	CI:	1.01-1.70).	The	lower	frequency	of	these	enzyme-altering	
alleles	in	non-Asian	populations	limits	the	use	of	MR	to	study	risk	factors	in	other	groups.	Large	
projects	 such	 as	 UK	 Biobank,	 which	 has	 genotyped	 SNPs	 and	 collected	 data	 on	 alcohol	
consumption	 in	 approximately	 500,000	 individuals	 (Bycroft	 et	 al.,	 2018),	 have	 led	 to	 the	
identification	of	 SNPs	associated	with	alcohol	 intake	 common	 in	other	populations	 (Clarke	et	
al.,	2017).	Additional	alcohol-associated	SNPs	will	facilitate	the	wider	use	of	MR	frameworks	to	
study	the	effect	of	alcohol	consumption	on	disease	risk.		
	
Dimitrakopoulou	 et	 al.	 (2017)	 used	 an	 MR	 strategy	 to	 investigate	 the	 relationship	 between	
vitamin	 D	 and	 the	 risk	 of	 seven	 cancers,	 including	 CRC,	 employing	 SNPs	 associated	 with	
circulating	25-hydroxyvitamin	D	(25-OHD)	as	IVs.	The	analysis	found	little	evidence	that	vitamin	
D	was	associated	with	increased	risk	of	any	of	the	cancers.	He	et	al.	(2018)	and	Theodoratou	et	
al.	(2012)	both	also	similarly	found	non-significant	associations	between	circulating	25-OHD	and	
CRC	risk.	These	data	do	not	support	the	results	of	observational	epidemiological	studies,	which	
have	 found	 circulating	 25-OHD	 to	 be	 associated	 with	 decreased	 CRC	 risk	 (Ma	 et	 al.,	 2011),	
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suggesting	that	the	observational	studies	could	be	biased	by	reverse	causality	or	confounding	
factors.	
	
Interleukin-6	(IL-6)	is	thought	to	influence	the	progression	of	several	forms	of	cancer	(Kumari	et	
al.,	 2016).	 An	 MR	 analysis	 of	 circulating	 IL-6	 concentrations	 and	 cancer	 risk	 was	 therefore	
performed	 by	 Tian	 et	 al.	 (2015),	 who	 did	 not	 find	 evidence	 of	 a	 causal	 relationship.	 This	 is	
concordant	 with	 the	 results	 of	 observational	 epidemiological	 studies,	 which	 have	 also	 not	
identified	IL-6	concentrations	to	be	associated	with	CRC	risk	(Zhou	et	al.,	2014).		
	
One	 of	 the	 earliest	 studies	 to	 use	 an	 MR	 framework	 to	 investigate	 CRC	 risk	 factors	 was	
conducted	by	Lin	et	al.	(2002),	who	used	a	polymorphism	in	PTGS2	(Val511Ala)	to	simulate	the	
effects	of	aspirin,	and	 thereby	 study	 the	 relationship	between	aspirin	use	and	CRC	 risk.	Non-
significant	 negative	 associations	 between	 the	 aspirin-simulating	 allele	 and	 CRC	 risk	 were	
reported,	 although	 the	 study	 sample	 sizes	 were	 small.	 The	 Val511Ala	 polymorphism	 is	 not	
common	in	some	populations,	including	Chinese,	Japanese	and	Caucasians,	prohibiting	its	study	
in	many	large	GWAS	data	sets	based	on	these	ethnicities	(Lin	et	al.,	2002).		
	
The	causal	relevance	of	telomere	length	to	various	cancers	has	also	been	interrogated	using	MR	
frameworks.	 Whilst	 two	 MR	 studies	 found	 genetically	 predicted	 longer	 telomeres	 to	 be	
associated	with	increased	risk	of	some	cancers,	including	glioma	and	lung,	no	association	with	
CRC	risk	was	identified	(Telomeres	Mendelian	Randomization	Collaboration	et	al.,	2017;	Zhang	
et	al.,	2015).	Retrospective	observational	studies	of	telomere	length	and	CRC	found	individuals	
diagnosed	with	CRC	to	have	shorter	telomeres	(Pooley	et	al.,	2010),	whilst	a	prospective	study	
identified	 no	 significant	 association	 between	 telomere	 length	 and	 CRC	 diagnosis	 (Zee	 et	 al.,	
2009).	 The	 results	 from	 the	 prospective	 study	 and	 MR	 studies	 suggest	 that	 the	 inverse	
relationship	identified	in	the	retrospective	study	is	likely	due	to	reverse	causation	(Fernandez-
Rozadilla	et	al.,	2018;	Pooley	et	al.,	2010).		
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6.	FUTURE	USES	OF	MENDELIAN	RANDOMISATION		
	
Whilst	MR	has	provided	 supporting	evidence	 for	a	number	of	 known	and	 suspected	CRC	 risk	
factors	 (Table	 1),	 there	 are	 many	 other	 putative	 CRC	 risk	 factors	 that	 have	 not	 yet	 been	
interrogated	 using	 MR	 frameworks,	 including	 coffee	 consumption	 and	 intake	 of	 foods	
containing	 calcium,	 iron	 or	 zinc	 (World	 Cancer	 Research	 Fund,	 2017).	 For	 some	exposures,	 a	
lack	 of	 associated	 SNPs	 explaining	 a	 substantial	 proportion	 of	 variance	 prevents	 their	
consideration.	As	GWAS	sample	sizes	continue	to	increase,	the	number	of	exposures	for	which	
there	is	sufficient	power	to	identify	small	or	moderate	effect	sizes	under	an	MR	framework	will	
grow.		
	
So	 far,	MR	 analyses	 of	 CRC	 risk	 have	 generally	 been	 hypothesis-driven	 (i.e.	 have	 considered	
exposures	 for	which	 there	 is	pre-existing	evidence	 for	an	effect	on	CRC	 risk).	Hypothesis-free	
MR	 has	 the	 potential	 to	 identify	 previously	 unsuspected	 risk	 factors	 not	 considered	 in	
observational	epidemiological	 studies	 (Evans	and	Davey	Smith,	2015).	 Tools	 such	as	MR-Base	
(Hemani	et	al.,	2018),	which	provides	MR	method	implementations	and	databases	of	collated	
GWAS	summary	statistics,	could	help	facilitate	such	hypothesis-free	scans.	
	
The	development	and	application	of	additional	techniques	will	also	help	robustly	infer	causality	
between	exposures	and	CRC	risk,	whilst	avoiding	biases	that	can	lead	to	false	positives.	GSMR	
improves	upon	the	power	of	other	summary-data-based	MR	methods	by	accounting	for	linkage	
disequilibrium	 between	 SNPs	 (Zhu	 et	 al.,	 2018),	 thereby	 avoiding	 the	 unnecessary	 loss	 of	
information.	LCV	models	can	identify	causal	relationships	between	genetically	correlated	traits,	
mediating	 such	 correlations	 with	 latent	 causal	 variables	 (O'Connor	 and	 Price,	 2018).	 This	
reduces	 the	number	 of	 false	 positives	 that	 can	occur	when	using	 other	 summary-data-based	
MR	approaches	with	genetically	correlated	traits	(O'Connor	and	Price,	2018).		
	
	
7.	CONCLUSION	
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Mendelian	 randomization	 has	 provided	 evidence	 supporting,	 and	 not	 supporting,	 the	 causal	
relationship	 between	multiple	 risk	 factors	 and	 CRC.	 Further	 study	 using	MR	 frameworks	will	
help	inform	public	health	strategies,	as	well	as	provide	better	understanding	of	CRC	aetiology.		
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Figure	1:	The	basic	instrumental	variable	(IV)	model	depicted	using	a	directed	acyclic	graph.	Z:	
the	 instrumental	 variable,	 X:	 the	 exposure	 of	 interest	 (such	 as	 a	 putative	 risk	 factor),	 Y:	 the	
outcome	of	interest	(such	as	a	disease),	U:	one	or	more	measured	or	unmeasured	confounders.	
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TABLES	
	
Risk	factor	 Reference	 Number	of	
CRC	cases	
Number	of	
controls	
Primary	findings	using	MR	
Adiponectin	 Song	et	al.	(2015)	 7,020	 7,631	 No	significant	association.			
	 Nimptsch	et	al.	(2017)	 1,253	 1,627	 No	significant	association.			
	 Pei	et	al.	(2015)	 NA	 NA	 Inconsistent	evidence.		
Age	at	
menarche	&	
menopause	
Neumeyer	et	al.	(2018)	 12,944	 10,741	 No	significant	association.		
Alcohol		 Wang	et	al.	(2011)	 2,392	 3,951	 Alcohol	consumption	associated	with	increased	CRC	risk	(OR:	
1.31,	95%	CI:	1.01-1.70).	
Aspirin	 Lin	et	al.	(2002)	 161	 219	 No	significant	association.			
C-reactive	
protein	(CRP)	
Wang	et	al.	(2018)	 30,480	 22,844	 No	significant	association.			
Nimptsch	et	al.	(2015a)	 727	 727	 CRP	concentration	associated	with	increased	CRC	risk	(OR:	
1.74,	95%	CI:	1.06-2.85).	
Fatty	acids	 May-Wilson	et	al.	(2017)	 9,254	 18,386	 Arachidonic	acid	(OR:	1.05,	95%	CI:	1.02-1.07,	P=1.7×10-4)	and	
stearic	saturated	fatty	acids	(OR:	1.17,	95%	CI:	1.01-1.35,	
P=0.041)	associated	with	increased	CRC	risk.	Oleic	(OR:	0.77,	
95%	CI:	0.65-0.92,	P=3.9×10-3)	and	palmitoleic	(OR:	0.36,	95%	
CI:	0.15-0.84,	P=0.018)	monounsaturated	fatty	acids,	and	
linoleic	polyunsaturated	fatty	acids	(OR:	0.95,	95%	CI:	0.93-
0.98,	P=3.7×10-4)	associated	with	reduced	CRC	risk.		
Fetuin-A	 Nimptsch	et	al.	(2015b)	 456	 456	 No	significant	association.			
Height	 Thrift	et	al.	(2015a)	 10,226	 10,286	 Height	associated	with	increased	CRC	risk	(OR:	1.07,	95%	CI:	
1.01-1.14).		
	 Khankari	et	al.	(2016)	 5,100	 4,831	 Height	associated	with	increased	CRC	risk	(OR:	1.58,	95%	CI:	
1.14-2.18,	P=0.006).		
Interleukin-6	 Tian	et	al.	(2015)	 10,257	 12,391	 No	significant	association.			
Lipids	 Rodriguez-Broadbent	et	al.	(2017)	 9,254	 18,386	 Higher	total	cholesterol	associated	with	increased	CRC	risk	
(OR:	1.46,	95%	CI:	1.20-1.79,	P=1.68×10-4).	Statin-effect-
simulating	HMGCR	polymorphism	associated	with	reduced	
CRC	risk	(OR:	0.69,	95%	CI:	0.49-0.99,	P=0.046).	No	significant	
associations	for	low-density	lipoprotein,	high-density	
lipoprotein	and	total	triglyceride.		
Obesity	 Jarvis	et	al.	(2016)	 9,254	 18,386	 BMI	(OR:	1.23,	95%	CI:	1.02-1.49,	P=0.033),	childhood	obesity	
(OR:	1.07,	95%	CI:	1.03-1.13,	P=0.018)	and	WHR	(OR:	1.59,	
95%	CI:	1.08-2.34,	P=0.019)	associated	with	increased	CRC	
risk.		
	 Thrift	et	al.	(2015b)	 10,226	 10,286	 BMI	associated	with	increased	CRC	risk	(OR:	1.50,	95%	CI:	
1.13-2.01).	
	 Gao	et	al.	(2016)	 5,100	 4,831	 Adult	BMI	(OR:	1.39,	95%	CI:	1.06-1.82,	P=0.016)	associated	
with	increased	CRC	risk.	Childhood	BMI	and	WHR	non-
significant.		
Telomere	
length	
Telomeres	Mendelian	
Randomization	Collaboration	et	al.	
(2017)	
14,537	 16,922	 No	significant	association.			
Zhang	et	al.	(2015)	 5,100	 4,831	 No	significant	association.			
Vitamin	D	 Dimitrakopoulou	et	al.	(2017)	 11,488	 84,418	 No	significant	association.			
	 He	et	al.	(2018)	 10,725	 30,794	 No	significant	association.				
	 Theodoratou	et	al.	(2012)	 2,001	 2,237	 No	significant	association.		
	
Table	1:	MR	studies	that	have	assessed	a	possible	causal	relationship	between	exposures	and	
CRC	risk.	
